Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

ZYMEWORKS INC.

(ZYME)
  Report
Real-time Estimate Cboe BZX  -  01:51:15 2023-01-30 pm EST
9.225 USD   -3.71%
01/25Zymeworks Announces Participation in Upcoming Investor Conferences
BU
01/20Jazz Pharmaceuticals and Zymeworks Announce 84% Overall Survival at 18 Months from Phase 2 Trial Evaluating Zanidatamab in HER2-Expressing Metastatic Gastroesophageal Adenocarcinoma
AQ
01/20SVB Securities Raises Price Target on Zymeworks to $10 From $8, Maintains Market Perform Rating
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news
Most relevant news about ZYMEWORKS INC.
01/25Zymeworks Announces Participation in Upcoming Investor Conferences
BU
01/20Jazz Pharmaceuticals and Zymeworks Announce 84% Overall Survival at 18 Months from Phas..
AQ
01/20SVB Securities Raises Price Target on Zymeworks to $10 From $8, Maintains Market Perfor..
MT
01/19Jazz Pharmaceuticals, Zymeworks Announce Positive Results From Phase 2 Trial of Esophag..
MT
01/19Jazz Pharmaceuticals and Zymeworks Announces 84% Overall Survival At 18 Months from Pha..
CI
01/12Transcript : Zymeworks Inc. Presents at 41st Annual J.P. Morgan Healthcare Co..
CI
01/04Zymeworks Updates on Cash Resources; Chief Medical Officer to Depart Amid Internal Reor..
MT
01/04Zymeworks Inc. Removes Neil Josephson from the Position of Chief Medical Officer
CI
01/04Zymeworks Provides Corporate Update on Key Strategic Priorities and Outlook for 2023
BU
01/04HC Wainwright Adjusts Price Target on Zymeworks to $8 From $10, Maintains Neutral Ratin..
MT
2022Jazz Pharmaceuticals And Zymeworks Announce Jazz Has Confirmed Opt-In And Advances Part..
AQ
2022Barclays Adjusts Zymeworks Price Target to $9 From $7, Maintains Equal Weight Rating
MT
2022Jazz Pharmaceuticals Exercises Option to Continue Exclusive Rights to Zymeworks' Zanida..
MT
2022Zymeworks Announces Participation in Upcoming Investor Conference
BU
2022Jazz Pharmaceuticals plc and Zymeworks Announce Jazz Has Confirmed Opt-In and Advances ..
CI
2022North American Morning Briefing: Futures Rise -2-
DJ
2022Zymeworks Announces Positive Topline Data in The Pivotal HERIZON-BTC-01 Trial Of Zanida..
AQ
2022Jefferies Upgrades Zymeworks to Buy From Hold, Adjusts Price Target to $11 From $7.70
MT
2022Zymeworks Reports Positive Topline Results in Clinical Trial for Biliary Tract Cancer T..
MT
2022Transcript : Zymeworks Inc. - Special Call
CI
2022Zymeworks Brief: Announcing "Positive" Topline Data in the Pivotal HERIZ..
MT
2022Zymeworks Inc. Announces Positive Topline Data in the Pivotal HERIZON-BTC-01 Trial of Z..
CI
2022Zymeworks Inc.(NasdaqGS:ZYME) added to NASDAQ Composite Index
CI
2022Zanidatamab Clinical Data Selected For Presentation At The American Society Of Clinical..
BU
2022Zymeworks Inc - New Clinical Data for Zanidatamab in HER2+ /HR+ Metastatic Breast Cance..
AQ
2022New Clinical Data for Zanidatamab in HER2+ /HR+ Metastatic Breast Cancer Presented Toda..
BU
2022Zymeworks Inc. Announces New Clinical Data for Zanidatamab in Her2+ /Hr+ Metastatic Bre..
CI
2022Zymeworks to Move Stock Listing to Nasdaq
MT
2022Zymeworks to Transfer Stock Listing to Nasdaq
BU
2022Zymeworks to Get Upfront Payment From Jazz Pharmaceuticals as Antitrust Period for Zani..
MT
2022Zymeworks Announces Expiration of Hart-Scott-Rodino Waiting Period for Zanidatamab Lice..
BU
2022Zymeworks Inc Announces Expiration of Hart-Scott-Rodino Waiting Period for Zanidatamab ..
CI
2022Zymeworks Announces Abstract For Zanidatamab In Late-Line HER2-Positive Hormone-Recepto..
AQ
2022Zymeworks Announces Participation in Upcoming Investor Conference
BU
2022HC Wainwright Adjusts Price Target on Zymeworks to $10 From $8, Maintains Neutral Ratin..
MT
2022Zymeworks Announces Abstract For Zanidatamab In Late-Line HER2-Positive Hormone-Recepto..
BU
2022Transcript : Zymeworks Inc., Q3 2022 Earnings Call, Nov 08, 2022
CI
2022Zymeworks Provides Corporate Update and Reports Third Quarter 2022 Financial Results
BU
2022Earnings Flash (ZYME) ZYMEWORKS Posts Q3 Loss $-0.66
MT
2022Zymeworks Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended Sep..
CI
2022North American Morning Briefing: Caution to -2-
DJ
2022HC Wainwright Downgrades Zymeworks to Neutral From Buy, Lowers Price Target to $8 From ..
MT
2022Stifel Adjusts Zymeworks' Price Target to $18 From $21, Reiterates Buy Rating
MT
2022SVB Securities Downgrades Zymeworks to Market Perform From Outperform, Adjusts Price Ta..
MT
2022Zymeworks Early R&D Day Highlights Progress in Development of Novel Pipeline Assets and..
BU
2022Transcript : Zymeworks Inc. - Special Call
CI
2022Sector Update: Health Care Stocks Ending Near Intra-Day Lows
MT
2022Sector Update: Health Care
MT
2022Top Midday Gainers
MT
2022Sector Update: Health Care Stocks Mixed Premarket Wednesday
MT
2022Transcript : Jazz Pharmaceuticals plc, Zymeworks Inc. - Special Call
CI
2022Jazz Pharmaceuticals, Zymeworks Enter Into Licensing Deal for HER2-targeted Bispecific ..
MT
2022Zymeworks To Host Conference Call on Exclusive Licensing Agreement of Zanidatamab
BU
2022Jazz Pharmaceuticals and Zymeworks Announce Exclusive License Agreement to Develop and ..
AQ
2022Jazz Pharmaceuticals and Zymeworks Announces Exclusive License Agreement to Develop and..
CI
2022Zymeworks to Host Third Quarter Results Conference Call
BU
2022Zymeworks Completes Plan to Become Delaware Corporation
BU
2022Zymeworks Inc. has Changed its Name to Zymeworks BC Inc
CI
2022Zymeworks : REPORT OF VOTING RESULTS - Form 8-K
PU
2022Zymeworks Announces Results of Special Meeting
AQ
2022Zymeworks Announces Results of Special Meeting
BU
2022Zymeworks Reminds Shareholders to Vote FOR its Redomicile
BU
2022Zymeworks Announces Participation in Upcoming Investor Conferences and Early Research a..
AQ
2022Zymeworks Announces Participation in Upcoming Investor Conferences and Early Research &..
BU
2022Independent Proxy Advisory Firm ISS Recommends a Vote FOR the Zymeworks Redomicile
BU
2022Zymeworks : Shareholder Director Nominations - Form 8-K
PU
2022Zymeworks Says Proxy Advisory Firm Glass Lewis Recommends Approval of Redomicile Plans
MT
2022Independent Proxy Advisory Firm Glass Lewis Recommends Zymeworks Shareholders Vote FOR ..
BU
2022Transcript : Zymeworks Inc. Presents at Morgan Stanley 20th Annual Global Hea..
CI
2022Citigroup Lowers Zymeworks Price Target to $21 From $27, Maintains Buy Rating
MT
2022Zymeworks Presents Early-Stage Results for Prospective Cancer Therapy
MT
2022Transcript : Zymeworks Inc. - Special Call
CI
2022Zymeworks Reports Preliminary Phase 1 Trial Results for Zanidatamab Zovodotin (ZW49) at..
BU
2022Zymeworks Inc. Reports Preliminary Phase 1 Trial Results for Zanidatamab Zovodotin At E..
CI
2022Zymeworks Announces Filing and Mailing of Materials for the Special Meeting to Approve ..
BU
1  2  3  4  5  6  7  8Next